🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

First treatment for acute migraine recommended by NICE - Pf Media bit.ly/3PCUFib

MHRA grants marketing authorisation for LEO’s dermatitis treatment - Pf Media bit.ly/3PuyHg8

Kyowa Kirin to acquire Orchard Therapeutics   - Pf Media bit.ly/3PRGWDc

VPAG survey – have your say - Pf Media bit.ly/3SGTsrC

MHRA licenses treatment option for rare autoimmune disease - Pf Media bit.ly/3HPljj8

Besins Healthcare appoints new General Manager - Pf Media bit.ly/3SD9T7b

NICE recommends Janssen’s rare disease treatment - Pf Media bit.ly/49TbGMl

SMC accepts AbbVie’s new Parkinson’s drug within NHS Scotland - Pf Media bit.ly/3TBz8Ix

Almirall expands pipeline to rare dermatological diseases - Pf Media: bit.ly/48VLPCv

HCP engagement solutions – being present isn’t enough - Pf Media bit.ly/4cthz4U

Research uncovers how to target dormant breast cancer cells and prevent relapse - Pf Media bit.ly/3Tyle8T

Positive trial results for PharmNovo's pain management drug - Pf Media bit.ly/4ctCIMx

Promising new treatment strategy for aggressive form of leukaemia - Pf Media bit.ly/4463eb5

NICE recommends new Novartis treatment for brain tumours - Pf Media bit.ly/44hxqQu

Novartis' leukaemia treatment to be made available on the NHS - Pf Media bit.ly/44qLjvz

Dare to be disruptive – how to model your European go to market strategy for success  - Pf Media bit.ly/3ytkpat

Go-to-market innovation in 2028: Essential disruption dimensions for thriving in the new European healthcare landscape - Pf Media bit.ly/3Vw2Mjm

Go-to-market innovation in 2028: Essential disruption dimensions for thriving in the new European healthcare landscape - Pf Media bit.ly/3RcqP4s

The impact of EU pharmaceutical reform - Pf Media bit.ly/3KQBWMQ

New MHRA Chief Executive Officer appointed - Pf Media bit.ly/3F2F2O6